: This application addresses broad Challenge Area (08) Genomics, and specific Challenge Topic 08-CA-101* Augmenting Genome-Wide Association Studies. The development of glioblastoma (GBM) has been hypothesized to be associated with relatively common germline alterations with limited penetrance. Collaborating with the group at the University of California at San Francisco (UCSF) we recently reported that SNPs mapping to 9p and 20q are associated with the development of GBM. We propose to characterize the germline alterations within these 9p and 20q regions and to correlate these with glioma 9p deletion and 20q gain.
Specific Aim 1 : Perform detailed germline genetic analysis of the associated 9p and 20q regions using 1200 cases and controls to determine the prevalence of known polymorphisms and new alterations.
Aim 1 a: Perform custom genotyping of 600 previously genotyped cases and matched controls for all non-redundant SNPs to better define haplotypes. Impute haploytpes and evaluate their association with GBM development.
Aim 1 b: Perform high-throughput sequencing of the ~200kb and ~100kb regions within 9p and 20, respectively, in 50 GBM cases and 50 controls that carry the imputed at-risk haplotypes. To directly determine haplotype structure, perform high-through-put sequencing of 50 isolated at-risk and non-risk chromosomes.
Aim 1 c: Custom genotype candidate polymorphisms in 600 new cases and matched controls to validate new alterations from Aims 1a and 1b.
Aim 1 d: Perform custom aCGH analysis of the 9p and 20q regions to ascertain copy number variants.
Specific Aim 2 : Perform detailed genetic analysis and expression analysis of gliomas from the cases.
Aim 2 a: Using FISH and custom CGHa define glioma 9p deletion and 20q gain status.
Aim 2 b: Sequence all exons in the 9p and 20q regions. Assess methylation of target gene promoters.
Aim 2 c: Evaluate the tumor expression of all known exons and miRNAs within the targeted regions. Determine the underlying GBM genetic subtype.
Specific Aim 3 : Correlate polymorphism/ alteration/haplotype prevalence differences and with acquired glioma alterations to generate a list of candidate germline 9p and 20q mutations likely to be associated with the development of gliomas. Gliomas cause significant morbidity and mortality. Approximately 18,500 people in the U.S. are diagnosed with glioma each year. Because most gliomas are biologically aggressive, approximately 12,800 people in the U.S. succumb to these tumors every year. Understanding the predisposition to gliomas will have major implications for the prevention of gliomas as well as the management of these tumors.

Public Health Relevance

Gliomas cause significant morbidity and mortality. Approximately 18,500 people in the U.S. are diagnosed with glioma each year. Because most gliomas are biologically aggressive, approximately 12,800 people in the U.S. succumb to these tumors every year. Understanding the predisposition to gliomas will have major implications for the prevention of gliomas as well as the management of these tumors.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
NIH Challenge Grants and Partnerships Program (RC1)
Project #
5RC1NS068222-02
Application #
7937827
Study Section
Special Emphasis Panel (ZRG1-ETTN-A (58))
Program Officer
Fountain, Jane W
Project Start
2009-09-30
Project End
2011-09-30
Budget Start
2010-09-01
Budget End
2011-09-30
Support Year
2
Fiscal Year
2010
Total Cost
$486,065
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Melin, Beatrice S; Barnholtz-Sloan, Jill S; Wrensch, Margaret R et al. (2017) Genome-wide association study of glioma subtypes identifies specific differences in genetic susceptibility to glioblastoma and non-glioblastoma tumors. Nat Genet 49:789-794
Pekmezci, Melike; Rice, Terri; Molinaro, Annette M et al. (2017) Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. Acta Neuropathol 133:1001-1016
Walsh, Kyle M; Codd, Veryan; Rice, Terri et al. (2015) Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget 6:42468-77
Walsh, Kyle M; de Smith, Adam J; Hansen, Helen M et al. (2015) A Heritable Missense Polymorphism in CDKN2A Confers Strong Risk of Childhood Acute Lymphoblastic Leukemia and Is Preferentially Selected during Clonal Evolution. Cancer Res 75:4884-94
Eckel-Passow, Jeanette E; Lachance, Daniel H; Molinaro, Annette M et al. (2015) Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. N Engl J Med 372:2499-508
Walsh, Kyle M; Codd, Veryan; Smirnov, Ivan V et al. (2014) Variants near TERT and TERC influencing telomere length are associated with high-grade glioma risk. Nat Genet 46:731-5
Cairncross, J Gregory; Wang, Meihua; Jenkins, Robert B et al. (2014) Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol 32:783-90
Walsh, Kyle M; Anderson, Erik; Hansen, Helen M et al. (2013) Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. Genet Epidemiol 37:222-8
Egan, Kathleen M; Wrensch, Margaret R; Jenkins, Robert B (2012) Rare and uncommon genetic variants may hold key to the 'missing heritability' in glioma. CNS Oncol 1:109-12
Jenkins, Robert B; Xiao, Yuanyuan; Sicotte, Hugues et al. (2012) A low-frequency variant at 8q24.21 is strongly associated with risk of oligodendroglial tumors and astrocytomas with IDH1 or IDH2 mutation. Nat Genet 44:1122-5

Showing the most recent 10 out of 15 publications